Axsome Therapeutics, Inc. (AXSM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 37.03 |
| Open | 35.85 |
| Bid | 37.91 x 1000 |
| Ask | 38.15 x 1000 |
| Day's Range | 34.69 - 39.73 |
| 52 Week Range | 19.38 - 71.50 |
| Volume | |
| Avg. Volume | 1,477,262 |
| Market Cap | 1.431B |
| Beta (5Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Barrons.com
Axsome Therapeutics Stock Soars on Proposed FDA Labeling for Depression Drug
Cowen analyst Joseph Thome said the disclosure is "an encouraging sign and hopefully an important step toward a potential near-term FDA approval" of Axsome's drug for major depressive disorder.
- Motley Fool
Tesla's Up as Stock-Split Investors Wait, But This Tiny Nasdaq Stock Is Riding High Monday
The stock market was in rally mode last week, and the good vibes looked like they were continuing after the weekend. As of 8:30 a.m., futures on the Nasdaq Composite (NASDAQINDEX: ^IXIC) led the market higher, rising about half a percent to climb above the 12,200 mark. Investors have been more interested in stock splits than ever, and some big-name companies have joined in the trend.
- Motley Fool
Why Axsome Therapeutics Stock Is On Fire Today
Axsome Therapeutics (NASDAQ: AXSM), a newly minted commercial-stage biopharma, is set for a strong session today. Ahead of the opening bell this morning, Axsome released an 8-K filing with the Securities and Exchange Commission revealing that it has received the proposed labeling from the Food and Drug Administration (FDA) for the experimental major depressive disorder drug known as AXS-05. The FDA reportedly sent Axsome this long-awaited regulatory update last Friday.
- Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid InhibitorBusiness Wire
- Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive DisorderBusiness Wire
